BVX - Bovie Medical Corporation
| Previous Close | 5.15 |
| Open | 5.15 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1000 |
| Day's Range | 5.04 - 5.18 |
| 52 Week Range | 2.17 - 5.49 |
| Volume | 76,131 |
| Avg. Volume | 114,893 |
| Market Cap | 169.332M |
| Beta | -1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.14 |
| Earnings Date | May 14, 2018 - May 18, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.67 |
- MarketWatch•8 days ago
Bovie Medical's stock jumps after deal to sell core business
Bovie Medical Corp.'s stock (bvx) soared 10% toward a 20-month high in premarket trade Monday, after the medical device company said it reached a deal to sell its "core" business and the Bovie brand for $97 million in cash to Symmetry Surgical Inc. As part of the deal, which is expected to close in the third quarter of 2018, Bovie said it will enter into transition services, patent licensing, disposables supply and generator manufacturing and supply agreements with Symmetry. "This is a milestone moment for the Company, one that creates significant value for our shareholders by significantly enhancing our balance sheet with the addition of more than $70 million in estimated net cash proceeds after taxes and transaction related expenses and allowing us to further focus the organization on our strategic objective of commercializing our J-Plasma/Renuvion technology in the cosmetic surgery market," said Chief Executive Charlie Goodwin.
- Business Wire•8 days ago
Bovie Medical Corporation Announces Agreement to Sell “Core” Business Segment to Symmetry Surgical, Inc. for Total Cash Consideration of $97 million
Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that the Company has entered into a definitive agreement with Specialty Surgical Instrumentation Inc., a subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which the Company will divest and sell the Core business segment and the Bovie® brand to Symmetry for gross proceeds of $97 million in cash. The asset purchase agreement was approved by the Company’s Board of Directors and is subject to customary closing conditions – including approval by the Company’s stockholders – and expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Business Wire•8 days ago
Bovie Medical Corporation Announces Preliminary Second Quarter 2018 Revenue Results
Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced preliminary revenue results for the second quarter of fiscal year 2018.
- Business Wire•2 months ago
Bovie Medical Corporation to Participate in the JMP Securities 2018 Life Science Conference
Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the JMP Securities 2018 Life Science Conference at the St. Regis New York in New York, New York. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Medical investor relations website at http://www.boviemedical.com/investor_relations/. Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue.
- ACCESSWIRE•2 months ago
Wired News - Microbot Medical Shares Results from the In-Vitro Study of its Self-Cleaning Shunt
LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Microbot Medical Inc. (NASDAQ: MBOT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBOT as the Company's latest news hit the wire. On May 21, 2018, the medical device Company, which is specializing in the design and development of transformational micro-robotic medical technologies, declared the results of its pre-clinical study evaluating the Company's Self-Cleaning Shunt (SCS). Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Microbot Medical.
- ACCESSWIRE•2 months ago
Blog Exposure - Valeritas Presented Positive Clinical Results from Two New Studies Assessing V-Go Wearable Insulin Delivery Device in Type-2 Diabetes
LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Valeritas Holdings, Inc. (NASDAQ: VLRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VLRX as the Company's latest news hit the wire. On May 18, 2018, the Company reported positive results from two new studies assessing its V-Go Wearable Insulin Delivery device, during poster presentations at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress held in Boston, Massachusetts. Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Valeritas Holdings.
- Benzinga•2 months ago
Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 14) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. (NYSE: ...
- Associated Press•2 months ago
Bovie: 1Q Earnings Snapshot
The Clearwater, Florida-based company said it had a loss of 3 cents per share. The medical device maker posted revenue of $9.9 million in the period. Bovie expects full-year revenue in the range of $41 ...
- Business Wire•2 months ago
Bovie Medical Corporation Reports First Quarter 2018 Financial Results; Reaffirms Fiscal Year 2018 Financial Outlook
Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its first quarter ended March 31, 2018.
- Business Wire•2 months ago
Bovie Medical Corporation Announces Completion of Enrollment in J-Plasma®/RenuvionTM Dermal Resurfacing Study
Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the completion of enrollment for the U.S. Investigational Device Exemption (IDE) clinical study of its J-Plasma/Renuvion technology for use in dermal skin resurfacing. “We are excited to announce that today we have enrolled the final patient in our dermal skin resurfacing study, which represents another important development in our strategy to build clinical support for our Renuvion technology and expand its clinical indications for use in the cosmetic surgery market,” said Charlie Goodwin, Chief Executive Officer.
- ACCESSWIRE•2 months ago
Bovie Medical Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 14, 2018 / Bovie Medical Corporation (NYSE American: BVX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern ...
- Business Wire•2 months ago
Bovie Medical Corporation Announces Appointment of Diane I. Duncan, M.D., FACS to Medical Advisory Board
Bovie Medical Corporation (BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Diane I. Duncan, M.D., FACS to the Company’s Medical Advisory Board. “Dr. Duncan joins our Medical Advisory Board with over 30 years of experience in private practice as a plastic surgeon,” said Charlie Goodwin, Chief Executive Officer.
- Business Wire•3 months ago
Bovie Medical Corporation to Release First Quarter of Fiscal Year 2018 Financial Results on May 14, 2018
Bovie Medical , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the first quarter of fiscal year 2018 will be released after the market closes on Monday, May 14.
- Business Wire•4 months ago
Bovie Medical Corporation Announces Launch of Renuvion™: A New Brand Dedicated to the Cosmetic Surgery Market
Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today announced the launch of Renuvion™, a new brand that is dedicated to the cosmetic surgery market.
- Business Wire•4 months ago
Bovie Medical Corporation Announces Appointment of Scott R. Sanders as Director of Clinical Education and Market Development
Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today announced the appointment of Scott R.
- Associated Press•4 months ago
Bovie reports 4Q loss
On a per-share basis, the Purchase, New York-based company said it had a loss of 3 cents. The medical device maker posted revenue of $11.3 million in the period. For the year, the company reported that ...
- Business Wire•4 months ago
Bovie Medical Corporation Reports Fourth Quarter and Full Year 2017 Financial Results; Provides Fiscal Year 2018 Financial Outlook
Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today reported financial results for its fourth quarter and full year ended December 31, 2017.
- Business Wire•4 months ago
Bovie Medical Corporation Announces Appointment of Craig A. Swandal to Board of Directors
Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today announced the appointment of Craig A.
- ACCESSWIRE•4 months ago
Bovie Medical Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Bovie Medical Corporation (Nyse American: BVX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018 at 4:30 PM ...
- Business Wire•4 months ago
Bovie Medical Corporation Announces Appointment of Dr. Topaz J. Kirlew as Director of Regulatory Affairs
Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced the appointment of Dr.
- Business Wire•5 months ago
Bovie Medical Corporation to Release Fourth Quarter and Fiscal Year 2017 Financial Results on March 12, 2018
Bovie Medical , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the fourth quarter and fiscal year of 2017 will be released after the market closes on Monday, March 12.
- Business Wire•6 months ago
Bovie Medical Corporation Announces Enrollment of First Patient in J-Plasma® Dermal Resurfacing Clinical Study
Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that it has enrolled the first patient in a U.S.
- Business Wire•7 months ago
Bovie Medical Corporation Appoints Charles D. Goodwin Chief Executive Officer; Updates 2017 Outlook
Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that Charles D.